- Data for SCULPTRA to support new administration method licensed in Europe that is fast and convenient
- ALLUZIENCE data to reaffirm effectiveness and safety of first ready-to-use liquid formulation licensed in Europe
- Galderma to host sponsored symposium to discuss initial assessment of different patient profiles, with live injections
- RESTYLANE EYELIGHT to launch as new targeted treatment solution for under-eye shadows
LAUSANNE, Switzerland--(BUSINESS WIRE)--Galderma today announced new results from its robust pipeline and portfolio of dermal fillers and toxin injections. Eleven e-posters from Galderma-sponsored and investigator-initiated trials have been accepted at the upcoming Aesthetic & Anti-Aging Medicine World Congress (AMWC), taking place in Monaco and virtually on September 16–18, 2021.
Data for SCULPTRA® (injectable poly-L-lactic acid) will explore the effectiveness and safety of two different dilutions (8mL versus 5mL) at 48 weeks for the correction of nasolabial fold wrinkles. Earlier this year, the administration procedure for SCULPTRA was updated in Europe, allowing for higher reconstitution volumes of 5-8mL (previously 5mL). These latest results serve to support the new protocol, which offers a faster and more convenient approach to injecting dermal fillers.
Further data will evaluate the effectiveness and safety of ALLUZIENCE® (liquid botulinum toxin type A) versus placebo after six months for the correction of glabellar (frown) lines. All currently approved botulinum toxin type A products in Europe come in powder form and require reconstitution before use.1 ALLUZIENCE—the first ready-to-use liquid formulation licensed in Europe—has been designed to deliver outstanding precision and performance, with a formulation developed using innovative new production technologies.1,2
“Our strong presence at AMWC this year underscores our unwavering commitment to driving aesthetics innovation. We understand that everyone’s skin is unique, and we embrace these differences to offer cutting-edge treatments that make people look and feel great. As we advance dermatology for every skin story, we are excited to be delivering novel solutions across our portfolio.”
FLEMMING ØRNSKOV, M.D., MPH
CHIEF EXECUTIVE OFFICER
GALDERMA
Taking the opportunity to engage with a variety of aesthetics and anti-aging experts, Galderma will host a sponsored symposium on Thursday, September 16, 2021, from 14:00-16:00 CEST in the prestigious Prince Pierre Auditorium. The interactive session, First Impressions – From Theory to Practice, will involve assessment with patient pictures, audience participation and live injections, led by a panel of multidisciplinary speakers covering the nose, skin and lips. More information and access to the event will be available to all registered congress participants.
The sponsored symposium will be followed on Friday, September 17, 2021, with a bespoke event, For Your Eyes Only, to launch RESTYLANE® EYELIGHT™, a new solution to combat under-eye shadows. The under-eye region is one of the first parts of the face to show signs of aging. This makes RESTYLANE EYELIGHT a major milestone for helping people look less tired and more rested, in addition to helping them feel their best.3,4 From 18:30-20:30 CEST, a world-renowned faculty will deliver an interactive agenda exploring the new opportunity and value of RESTYLANE EYELIGHT to clinical practice. Access to the event is invitation-only.
Additional data showcasing the strength and depth of Galderma’s pipeline and portfolio will be available throughout AMWC 2021. The complete list of 11 e-posters that have been accepted for presentation are:
|
Treatment |
E-poster |
Number |
|
SCULPTRA |
A randomized study on safety and effectiveness of a biostimulatory poly-L-lactic acid injectable implant after changes in reconstitution – Palm M., et al. |
Abstract #2343 |
|
ALLUZIENCE |
Treatment of moderate-to-severe glabellar lines using ready-to-use liquid abobotulinumtoxinA: Pooled data from two double-blind, randomized, placebo-controlled Phase III studies – Kestemont P., et al. |
Abstract #2340 |
|
ALLUZIENCE |
Long-lasting improvement of glabellar lines using ready-to-use liquid abobotulinumtoxinA: Post hoc analysis of a double-blind, randomized, placebo-controlled Phase III study – Kestemont P., et al. |
Abstract #2341 |
|
DYSPORT®** |
A randomized, double-blind, placebo-controlled study of a new dilution and injection volume of abobotulinumtoxinA for treatment of glabellar lines – Schlessinger J., et al. |
Abstract #2324 |
|
DYSPORT |
A randomized, dose-escalating, double-blind study to evaluate abobotulinumtoxinA for the treatment of moderate-to-severe glabellar lines – Joseph J., et al. |
Abstract #2462 |
|
DYSPORT |
Subject satisfaction with abobotulinumtoxinA for moderate-to-severe glabellar lines: A randomized, dose-escalating, double-blind study – Dayan S., et al. |
Abstract #2461 |
|
DYSPORT
|
Subject-relevant outcomes of on-label 50U abobotulinumtoxinA treatment for moderate-to-severe glabellar lines across three individual trials – Cox SE., et al. |
Abstract #2460 |
|
DYSPORT |
Subject satisfaction with two treatments a year (every six months) of abobotulinumtoxinA is high among both previously treated and toxin-naive cohorts – Cohen J., et al. |
Abstract #2527 |
|
DYSPORT |
Millennial subject satisfaction with two treatments of abobotulinumtoxinA a year – Cohen J., et al. |
Abstract #2529 |
|
RESTYLANE |
A randomized, controlled, evaluator-blinded study of HA-RD for chin augmentation and correction of chin retrusion – Moradi A., et al. |
Abstract #2323 |
|
RESTYLANE |
A randomized, evaluator-blinded, comparator-controlled study to evaluate HA-RV for cheek augmentation and correction of midface contour deficiencies – Moradi A., et al. |
Abstract #2339 |
